www.fdanews.com/articles/177613-roches-blood-cancer-candidate-fails-in-phase-3
Roche’s Blood Cancer Candidate Fails in Phase 3
July 20, 2016
Roche’s blood cancer candidate Gazyva floundered in a Phase 3 trial against Rituxan, missing its primary endpoint of improving progression-free survival.
The head-to-head study gauged the effectiveness of Gazyva taken in conjunction with chemotherapy versus rituximab taken with and chemotherapy for patients with untreated diffuse large b-cell lymphoma.
Gazyva, which falls under a joint venture between Genentech and Biogen, is a monoclonal antibody intended to attach to a protein found in some b-cells.